Stock DNA
Pharmaceuticals & Biotechnology
SEK 100 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.14
-117.45%
2.47
Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Jun 2025)
Net Profit:
-12 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-94.59%
0%
-94.59%
6 Months
-94.59%
0%
-94.59%
1 Year
-94.59%
0%
-94.59%
2 Years
-93.86%
0%
-93.86%
3 Years
-93.93%
0%
-93.93%
4 Years
-93.65%
0%
-93.65%
5 Years
-81.05%
0%
-81.05%
Nanologica AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.41%
EBIT Growth (5y)
-27.67%
EBIT to Interest (avg)
-9.73
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.34
Sales to Capital Employed (avg)
-0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.06
EV to EBIT
-1.59
EV to EBITDA
-2.24
EV to Capital Employed
2.72
EV to Sales
4.22
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-170.47%
ROE (Latest)
-116.71%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
2.30
10.80
-78.70%
Operating Profit (PBDIT) excl Other Income
-7.60
-5.70
-33.33%
Interest
1.50
1.10
36.36%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-12.30
-10.20
-20.59%
Operating Profit Margin (Excl OI)
-4,598.70%
-871.00%
-372.77%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -78.70% vs 61.19% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -20.59% vs 27.14% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
14.50
1.40
935.71%
Operating Profit (PBDIT) excl Other Income
-49.40
-57.70
14.38%
Interest
6.30
5.70
10.53%
Exceptional Items
-1.40
-4.70
70.21%
Consolidate Net Profit
-65.60
-75.20
12.77%
Operating Profit Margin (Excl OI)
-3,915.30%
-45,039.50%
4,112.42%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 935.71% vs -12.50% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 12.77% vs -36.23% in Dec 2023
About Nanologica AB 
Nanologica AB
Pharmaceuticals & Biotechnology
Nanologica AB (publ) is a Sweden-based materials development company. The Company specializes in developing nanoporous materials from nanoporous silica (silicon dioxide) for a variety of applications, ranging from purification to pharmaceutical excipients. The Company's core competency has been developed and expanded in two areas of application, in particular: Drug Delivery and Chromatography, a technology used for the separation and purification of products on the market and in development. The Company's Drug Delivery sector operates within a niche domain of nanocarriers. Nanologica AB (publ)’s drug delivery technology is aimed on absorption of the medicine by the body for drugs that are poorly soluble in water.
Company Coordinates 
Company Details
Forskargatan 20 G , SODERTALJE None : 151 36
Registrar Details






